PISCATAWAY, N.J. – Camber Pharmaceuticals announces the addition of emtricitabine and tenofovir disoproxil fumarate tablets to their current portfolio.
Emtricitabine and tenofovir disoproxil fumarate tablets is a two-drug combination of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 37 lbs.
Emtricitabine and tenofovir disoproxil fumarate tablets from Camber are available in a 200 mg/300 mg strength, in 30 count bottles.
Comments are closed.